ARID1A and ovarian cancer: Furthermore, empirical evidence from syngeneic mouse models demonstrates that ARID1A‐deficient ovarian cancer cells lead to a marked escalation in TILs and CD8 protein clusters, as opposed to their ARID1A‐wild‐type counterparts.240